BlackRock Throg Tst Portfolio Update

 
TIDMTHRG 
 
BLACKROCK THROGMORTON TRUST PLC (LEI: 5493003B7ETS1JEDPF59) 
 
 
All information is at 28 February 2018 and unaudited. 
Performance at month end is calculated on a cum income basis 
 
                                      One    Three      One     Three      Five 
                                    Month   months     year     years     years 
                                        %        %        %         %         % 
 
Net asset value                      -2.0      2.4     23.2      65.7     120.8 
 
Share price                           0.2      6.9     28.8      78.1     135.0 
 
Benchmark*                           -3.2     -2.9      8.7      29.4      62.9 
 
Sources: BlackRock and Datastream 
 
*With effect from 1 December 2013 the Numis Smaller Companies excluding AIM 
(excluding Investment Companies) Index replaced the Numis Smaller Companies 
plus AIM (excluding Investment Companies) Index as the Company's benchmark. The 
five year period indices have been blended to reflect this. 
 
At month end 
 
Net asset value capital only:                                         547.65p 
 
Net asset value incl. income:                                         548.84p 
 
Share price                                                           482.00p 
 
Discount to cum income NAV                                              12.2% 
 
Net yield1:                                                              1.9% 
 
Total Gross assets2:                                                  GBP401.4m 
 
Net market exposure as a % of net asset value3:                        111.2% 
 
Ordinary shares in issue4:                                         73,130,326 
 
2017 ongoing charges* (excluding performance fees5,6:                    0.9% 
 
2017 ongoing charges* ratio (including performance fees)                 2.2% 
5,6,7: 
 
 
*Ongoing Charges: The recent management fee rate reductions, as detailed in the 
notes below, will impact management fees in 2017 and onwards.   The impact of 
the new fee arrangements, assuming the same level of performance from the 
manager and assuming all other charges remain the same, would be to reduce the 
level of Ongoing Charges borne by the trust. 
 
1. Calculated using 2017 interim dividend declared on 24 July 2017 and 2017 
final dividend declared on 12 February 2018. 
 
2. Includes current year revenue and excludes gross exposure through contracts 
for difference. 
 
3. Long positions less short positions as a percentage of net asset value. 
 
4. Excluding 7,400,000 shares held in treasury. 
 
5. Calculated as a percentage of average net assets and using expenses, 
excluding performance fees and interest costs for the year ended 30 November 
2017. 
 
6. With effect from 1 August 2017 the base management fee was reduced from 
0.70% to 0.35% of gross assets per annum. 
 
7. Effective 1st December 2017 the annual performance fee arrangements for the 
Company have changed.  The annual performance fee is now calculated using 
performance data on an annualised rolling two year basis (previously, one year) 
and the maximum annual performance fee payable is effectively reduced to 0.90% 
of two year rolling average month end gross assets (from 1% of average annual 
gross assets over one year). Additionally, the Company now accrues this fee at 
a rate of 15% of outperformance (previously 10%). The maximum annual total fees 
(comprising the base management fee of 0.35% and a potential  performance fee 
of 0.90%) will therefore fall to 1.25% of average month end gross assets on a 
two year rolling basis (from 1.70% of average annual gross assets). 
 
Sector Weightings                                           % of Total Assets 
 
Industrials                                                              35.0 
 
Financials                                                               19.1 
 
Consumer Services                                                        16.1 
 
Consumer Goods                                                            9.9 
 
Basic Materials                                                           6.2 
 
Health Care                                                               6.0 
 
Technology                                                                5.8 
 
Oil & Gas                                                                 2.0 
 
Net current liabilities                                                  -0.1 
 
                                                                        ----- 
 
Total                                                                   100.0 
 
                                                                        ===== 
 
Market Exposure (Quarterly) 
 
                        31.05.17       31.08.17        30.11.17        28.02.18 
                               %              %               %               % 
 
Long                       117.3          115.3           116.9           119.6 
 
Short                        6.1            5.8             6.3             8.4 
 
Gross exposure             123.4          121.1           123.2           128.0 
 
Net exposure               111.2          109.5           110.6           111.2 
 
 
 
Ten Largest Investments 
 
Company                                               % of Total Gross Assets 
 
Melrose Industries                                                        3.1 
 
Dechra Pharmaceuticals                                                    2.8 
 
Ascential                                                                 2.8 
 
4imprint Group                                                            2.6 
 
Robert Walters                                                            2.4 
 
CVS Group                                                                 2.3 
 
Ibstock                                                                   2.1 
 
Bodycote                                                                  2.0 
 
Johnson Service Group                                                     2.0 
 
SSP                                                                       2.0 
 
Commenting on the markets, Dan Whitestone, representing the Investment Manager 
noted: 
 
During February the Company's NAV per share fell by 2.0% to 548.84p on a cum 
income basis whilst our benchmark (the Numis Smaller Companies excluding AIM 
(excluding Investment Companies Index) fell by 3.2%; the FTSE 100 Index fell 
4.0% (all performance figures are with income reinvested and net of ongoing 
charges and any applicable performance fees). 
 
Positive stock selection in both long and short positions drove outperformance 
over the benchmark during the month. 
 
Ascential, a core holding, performed well after the company announced solid 
full year results where Earnings Per Share (EPS) beat expectations by 4% and a 
confident outlook: organic revenue and profit growth to accelerate. Integrafin, 
a fast growing UK financial services company, which we purchased at Initial 
Public Offering (IPO) during the month, and where we have strong conviction in 
the growth prospects for the company and potential for valuation uplift, made a 
positive start to its life as a listed company. Dechra Pharmaceuticals reported 
interim results for the six months to 31 December 2017, showing strong revenue 
growth in both Europe and North America while management stated that current 
trading remains in line with expectations. 
 
Whilst short positions benefitted in general from a falling market, we had some 
strong wins with our shorts in a UK roadside assistance company and a UK bus 
and rail company. Both have high leverage and have seen profits falling.  Given 
interest rate uncertainty, it does seem right now that the market is focusing 
more and more on balance sheets and cashflow, rather than just EPS and P/E 
(price to earnings) ratios, so this should bode well for many of our shorts. 
 
Shares in Sophos fell after the company reported results reiterating full year 
guidance, but noted a slight reduction in its renewal rate. While the decline 
in the renewal rate was disappointing, Sophos remains an attractive investment 
given its market leading position in the fast growing cyber security space. 
 
Activity during February included adding to SSP Group and Melrose Industries 
and purchasing a new holding in Integrafin as mentioned above. We continue to 
use market volatility to add to existing holdings where we feel the valuation 
does not reflect the true earnings potential of these companies. 
 
16 March 2018 
 
ENDS 
 
Latest information is available by typing www.blackrock.co.uk/thrg on the 
internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV 
terminal).  Neither the contents of the Manager's website nor the contents of 
any website accessible from hyperlinks on the Manager's website (or any other 
website) is incorporated into, or forms part of, this announcement. 
 
 
 
END 
 

(END) Dow Jones Newswires

March 16, 2018 09:37 ET (13:37 GMT)